Tweets
Expert Perspective on Calcium Pyrophosphate Deposition Disease
A current perspective article by Dr. Sara Tedeschi tackles many unresolved issues around CPPD diagnosis, classification, and management, including the lack of clinical trials or FDA approved treatments. https://t.co/zxJ9aQweNl
Dr. John Cush @RheumNow ( View Tweet )
1 hour 14 minutes ago
Pragmatism in Gout: How therapeutic choices can have multiple benefits
William James famously wrote in Pragmatism, “There can be no difference anywhere that doesn’t make a difference elsewhere.” Gout treatment offers a striking medical example of that idea. https://t.co/DG29pro6XE
Dr. John Cush @RheumNow ( View Tweet )
15 hours 14 minutes ago
Gout and its' associated comorbidities - treat gout and its' comorbidities to target
https://t.co/U0dolcAGEc https://t.co/mGvYQrWx25
Dr. John Cush @RheumNow ( View Tweet )
16 hours 45 minutes ago
Among 784,091 pts in a UK acute MI registry, 715 (0.1%) had SLE. SLE pts were younger & more female. SLE w/ MI had signif higher adjusted all-cause mortality from 30 days (HR 1.62) to 5 years (HR 1.84), despite age & having less traditional cardiovascular comorbidities https://t.co/78oHVWTdTJ
Dr. John Cush @RheumNow ( View Tweet )
20 hours 14 minutes ago
Nerandomilast (Jascayd) has been approved in the European Union for adults with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). The drug was approved for IPF & PPF by the FDA for US use in late 2025 https://t.co/scOuVb3aYy https://t.co/EcmpRhyWgu
Dr. John Cush @RheumNow ( View Tweet )
22 hours 14 minutes ago
Coding: ICD-10 Code M45.7 describes ankylosing spondylitis of the lumbosacral region, a billable ICD-10-CM diagnosis code valid for FY2026. M45.7 became effective October 1, 2025 and belongs to the M45 parent category covering ankylosing spondylitis by anatomical site. https://t.co/jBmoD0CVps
Dr. John Cush @RheumNow ( View Tweet )
23 hours 44 minutes ago
Chinese cohort of 209 AOSD pts identifed 49 (23%) w/ lung dz (by CXR), yet 69% were asymptomatic. Significcant risk factors for AOSD-LD were pleuritis, MAS (HR 2.62), & Dz relapse (HR 2.6). Imaging patterns: acute exudative pattern most prevalent, followed by interstitial and https://t.co/2IPJWRJicP
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
The Hidden Cost of Gout
For many people, gout is viewed as an episodic disease: a painful flare, a short course of treatment, and then life returns to normal. However, as rheumatologists, we know that recurrent attacks can lead to joint damage and tophi if left untreated. https://t.co/RWTp5KKkyw
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
Fibromyalgia: Diagnosis and Management
https://t.co/L9nA1TlJKx https://t.co/G4bkxTsXCt
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
EUSTAR scleroderma substudy propensity matched pts Rx w/ JAKi (n 38) vs 180 pts ea Rx w/ MMF, MTX, RTX. 1/3 had dcSSc. 23 AEs in 997 Pt-yrs. JAKi outcomes similar to comparators. JAKi Tx D/C in 39%, FVC stable, skin fibrosis improved (mRSS −1.8) & SJC decreased. No new
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
QD Clinic: Gout, Sepsis… or Both?
Dr. Mrinalini Dey, London, discusses a complex case.
https://t.co/UtncfZgZyL https://t.co/xVTA0LnPpN
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
The Lancet Rheumatology has a good editorial about the avacopan bad news reports with EMA, FDA and Japan issuing negative opinions that threaten the drugs future. Yet, since approval real world data on avacopan has been favorable w/ less steroid toxicity & most hepatotoxicity https://t.co/k6ebVeWv2K
Dr. John Cush @RheumNow ( View Tweet )
1 day ago


